Evidence map›Paper›PMID 37649434›Full record

ArticleEmerging microbes & infections2023

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen.

Joseph Jelinski, Monika M Kowatsch, Marc-Alexandre Lafrance, Alice Berger, Jannie Pedersen, Hiva Azizi, Yue Li, Florine Scholte, Alejandro Gomez, Natasha Hollett and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Joseph JelinskiDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Monika M KowatschDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Marc-Alexandre LafranceFaculty of Medicine, Université Laval, Quebec City, Canada.
Alice BergerDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada.
Jannie PedersenAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada.
Hiva AziziDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada.
Yue LiDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada.
Florine ScholteDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada.
Alejandro GomezDépartement de Microbiologie-Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada.
Natasha HollettDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Toby LeDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Matthew WadeAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada.
Hugues Fausther-BovendoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Marc-Antoine de La VegaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
George BabuadzeDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Ara XiiiDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Claude LamarreAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada.
Trina RacineAxe des Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada.
Chil-Yong KangDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada.
Xiao-Jian YaoDepartment of Medical Microbiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Eric ArtsDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada.
Keith R FowkeDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Gary P KobingerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · USUniversity of Manitoba · CAUniversité Laval · CACentre hospitalier universitaire de Québec · CAWestern University · CACenters for Disease Control and Prevention · USCentre hospitalier de l'Université Laval · CAHarvard University · US

Funding

Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
NIAID NIH HHS R01 AI049170
6 · The paper itself

Abstract

Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.

Indexed as

HIV InfectionsVaccinesAnimalsAntigens, ViralMacaca mulattaPostoperative ComplicationsUp-RegulationVesiculovirusAntigens, ViralVaccinesHIVIFN-γimmunodeficiencyNHPprophylaxisT-cellvaccine

Identifiers

PMID37649434
PMCPMC10486302
OpenAlexW4386306149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.